Cargando…

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin

BACKGROUND: In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagliptin did not increase the risk for major CV adverse events. However, there was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pollack, Pia S., Chadwick, Kristina D., Smith, David M., Billger, Martin, Hirshberg, Boaz, Iqbal, Nayyar, Boulton, David W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598064/ https://www.ncbi.nlm.nih.gov/pubmed/28903775 http://dx.doi.org/10.1186/s12933-017-0595-6

Ejemplares similares

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
por: Perl, Shira, et al.
Publicado: (2016)

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
por: Sjöstrand, Mikaela, et al.
Publicado: (2017)

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Nonclinical Safety Pharmacology Study of the Herbal Product HAD-B1
por: Kim, Soo-Dam, et al.
Publicado: (2021)

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
por: Toth, Peter P
Publicado: (2014)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Strategies for the Nonclinical Safety Assessment of Vaccines
por: Wolf, Jayanthi J., et al.
Publicado: (2012)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Essential nonclinical competencies for cardiovascular specialists imperatives for training
por: Valentine, C. Michael, et al.
Publicado: (2022)

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
por: Patel, Chirag G, et al.
Publicado: (2011)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4‐Mediated Metabolism of Saxagliptin
por: Butrovich, Morgan A., et al.
Publicado: (2022)

Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients
por: Garg, Rajesh, et al.
Publicado: (2017)

Book Review: Toxicologic Pathology, Nonclinical Safety Assessment
por: Yoshizawa, Katsuhiko
Publicado: (2014)

Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
por: Fisher, J. Edward
Publicado: (2021)

Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
por: Moffit, Jeffrey S., et al.
Publicado: (2022)

Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations
por: Hirshberg, Boaz, et al.
Publicado: (2013)

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
por: Hirshberg, Boaz, et al.
Publicado: (2011)

Practical approaches for evaluating adrenal toxicity in nonclinical safety assessment
por: Inomata, Akira, et al.
Publicado: (2015)

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2018)

Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711
por: Lindström, Erik, et al.
Publicado: (2018)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Nonclinical Development of BCG Replacement Vaccine Candidates
por: Velmurugan, Kamalakannan, et al.
Publicado: (2013)

Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Men, Peng, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
por: Vaidya, Varun, et al.
Publicado: (2016)

Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers
por: Mansour, Rania Y., et al.
Publicado: (2022)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
por: Farr, Amanda M, et al.
Publicado: (2016)

The Clinical and Nonclinical Values of Nonexercise Estimation of Cardiovascular Endurance in Young Asymptomatic Individuals
por: Alomari, Mahmoud A., et al.
Publicado: (2012)

The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
por: Janas, Maja M., et al.
Publicado: (2018)

Nonclinical statistics for pharmaceutical and biotechnology industries
por: Zhang, Lanju
Publicado: (2016)

Cardiovascular Safety Pharmacology of Sibutramine
por: Yun, Jaesuk, et al.
Publicado: (2015)

Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro‐arrhythmia Assay initiative studies
por: Ligneau, Xavier, et al.
Publicado: (2017)

Cryolipolysis: Clinical Best Practices and Other Nonclinical Considerations
por: Few, Julius, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_thh7lkc0deneat19df1aav6jkm